Table 7.

Summary of time (duration) to recovery from grade 2 or more-severe neutropenia to grade 1 or less (safety population)

Duration (days) of ≥grade 2 neutropeniaaNo. (%) of patients
Phase II studybPhase III studyc
Peramivir (n = 198)Placebo (n = 100)Peramivir (n = 723)Oseltamivir (n = 363)
10 (0.0)0 (0.0)0 (0.0)0 (0.0)
2–30 (0.0)0 (0.0)0 (0.0)0 (0.0)
4–90 (0.0)0 (0.0)66 (90.4)25 (73.5)
10–1414 (77.8)2 (50.0)4 (5.5)6 (17.6)
≥154 (22.2)2 (50.0)3 (4.1)1 (2.9)
No recovery0 (0.0)0 (0.0)0 (0.0)2 (5.9)d
Total1847334
  • a Calculated as (date of recovery to grade 1 or less-severe neutropenia) − (date of onset of grade 2 or more-severe neutropenia) + 1.

  • b A placebo-controlled randomized study (12).

  • c An oseltamivir-controlled randomized study (our present study).

  • d Patients were categorized as “not recovered” because follow-up was discontinued.